Status: Not yet recruiting
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: Moein AminUpdated: May 20, 2026Locations: 1
Eligibility criteria
Written informed consent signed by participant. [+10]
Concurrent treatment with any disease modifying therapy for MS or systemic immun... [+22]